Apnimed, Inc. APMD
Set alert
At close · Oct 30
After hours · Oct 30, 5:24 PM ET
- YTD
- -34.40%
- 1 year
- -34.40%
- Open
- 17.10
- Prev close
- 17.34
- Mkt cap
- 682.74M
- Vol
- 466.52K
- Avg vol
- 508.85K
- EPS
- 7.22
- P/E
- 2.27
- Div yield
- 0.00%
More statistics
- Low
- 16.16
- High
- 17.36
- Forward P/E
- -6.42
- Beta
- 0.00
- Short ratio
- 1.05
- Inst. own
- 18.53%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 27.74
- 200-d avg
- 27.74
- 1y target
- 50.33
News
2 weeks ago globenewswire.com
Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026
CHEST-led panel to showcase data from the Phase 3 SynAIRgy and LunAIRo trials, exploring potential new paradigms for advancing OSA patient management CHEST-led panel to showcase data from the Phase 3…
4 weeks ago globenewswire.com
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and…
1 month ago defenseworld.net
Apnimed, Inc. (NASDAQ:APMD) Stock Short Interest Jumps 55.7%
Apnimed, Inc. (NASDAQ: APMD - Get Free Report) saw a significant increase in short interest in the month of September. As of September 15th, there was short interest totaling 879,684 shares, an…
1 month ago defenseworld.net
Apnimed, Inc. (NASDAQ:APMD) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Apnimed, Inc. (NASDAQ: APMD - Get Free Report) have been given an average rating of "Moderate Buy" by the five research firms that are covering the firm, MarketBeat.com reports. One…
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47%…
1 month ago seekingalpha.com
Apnimed: What We Know Heading Into The Feb PDUFA
Apnimed, Inc. (APMD) is a late-stage, de-risked regulatory play with a fully funded path to commercialisation, focused on AD109 for obstructive sleep apnea (OSA). AD109 (Oxnimbi) demonstrated robust…
1 month ago globenewswire.com
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and…
1 month ago globenewswire.com
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late stage clinical pharmaceutical company dedicated to the discovery, development…
1 month ago defenseworld.net
Apnimed, Inc.’s Quiet Period Will End on September 9th (NASDAQ:APMD)
Apnimed's (NASDAQ: APMD - Get Free Report) quiet period is set to expire on Wednesday, September 9th. Apnimed had issued 12,000,000 shares in its public offering on July 31st. The total size of the…
2 months ago proactiveinvestors.com
Apnimed shares surge on bullish BofA initiation
Shares of Apnimed rose 8% Tuesday after BofA Securities initiated coverage of the company with a Buy rating and a $41 price target. The rating is based on a risk-adjusted discounted cash flow…
2 months ago benzinga.com
This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.
2 months ago 247wallst.com
Apnimed's Nasdaq Debut Bets Big on a Pill to Dethrone CPAP Masks
The Nasdaq debut of Apnimed (NASDAQ:APMD) has given public investors their first pure-play bet on a pill for obstructive sleep apnea (OSA).
2 months ago globenewswire.com
Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and…
2 months ago benzinga.com
AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures higher, AstraZeneca dips on merger talks, Apple down 7.4%, other stocks moving lower in pre-market trading.
2 months ago benzinga.com
Why Atkore Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket
Atkore Inc (ATKR) shares rise on strong Q3 results and acquisition by Prysmian for $95.00 per share. Other gainers include UPC, YYAI, RITR, FCUV, SGLY, FNGR, ALAR, FERG, and BMY while FMFC, PWCM,…
3 months ago reuters.com
Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO
Late-stage drug developer Apnimed is targeting a valuation of up to $608 million in its initial public offering in the United States.
3 months ago seekingalpha.com
Apnimed Seeks IPO For OSA Treatment Commercialization
Apnimed, Inc. is pursuing an IPO to fund regulatory approval and initial commercialization of its lead OSA drug, Oxnimbi (AD109). AD109 has shown strong efficacy in Phase 3 trials and an FDA decision…